Good evening, ladies and gentlemen.
This is Itagaki.
I will start explaining the slides.
Please look at the second page.
It is a financial overview.
quarter, ¥XXX.X third cumulative the revenue billion. was In
and and reached income income highs was by sales billion, ¥XXX.X year. consecutive which Operating grew both double the fourth for record digits,
year progress generally performed XX.X% the well a forecast. Revenue rate with compared of to full
Operating been exceeding income XX%. have quarterly income and strong,
of is Before third the business results, X summary in have would in are occurred a the launched details updates. have last like page. The events the to blue financial the getting of that the touch ENSPRYNG Japan Please expansion. events Tecentriq related listed pipeline. development been was to the see indication approved August. months. in It U.S. the KADCYLA and into of approved for I upon some in in and
the pipelines R&D discuss will data section. We in
I here, So are that focus events black. will in the on
there three and a Over digital. months, of ESG the has talk about been last lot
of we Trade the to to promote as various pandemic are life. a medical and investment ESG selected year. an X In response achieved the the management session that to demonstration will ESG, and we the held influence with we be Economy sustainability Both pharmaceutical DX continue such base, DATA. joint and ESG economic, has were digital Exchange In of began adopted of of important continue August. September, as in and last social and did stocks GPIF our Industry August, index as sustainable designated COVID-XX we of themes In terms DX industry, X briefing disruptively introduction as the results on completion the works the activities. company In of line support and as one them. test In September, using with in a by Biofourmis July. we field, Ministry AI Tokyo we these from NTT development in brand by Stock
spread financial summarized There of impact I significant the our what COVID-XX actually kind no page, on the results. value chain. of has on is fourth the On impact negative
the profits, have the to of of exports the has market. in the But impact Hemlibra of strong absorbed terms of negative to inpatients. and sales the due decrease been of activities fully introduction the and self-restraint Tecentriq number the market In domestic the delayed
of each digitalization, Taking the styles, value company of this some that Although the each realize like function affected, as chain. and are speed we'd change improvements is activities the and development process an into recovered business be of working and further it efficiency, up opportunity, promote eventually. change to within can range productivity
growth I and plus profit increase turn of will billion, a of loss. Now billion, from increase financial of ¥XX.X It Please the up. billion, of year-on-year here, enter revenues sales and is other X. We Page outlined, into record a two: of explanation was posted divide the XX.X%. Revenue income ¥XX.X X.X%; plus detailed ¥XX.X ¥XXX.X to and operating royalties were XX.X% billion, an results.
As of generics. sales due price breakdown drug each, for decreased X.X% of revisions and by effect to the domestic the
due to billion increase increase XX.X%. of of caused a sales COVID-XX shipment resulting On ¥XX.XX by an price, and increased significant the at a Actemra sales overseas regular hand, in in other by exports Hemlibra
the total increasing to of fact of the X.X% self-restraint billion Selling due R&D development X decreased activities, to years the increased profit-sharing billion a since Hemlibra expenses sales expenses ¥X.X ¥X onetime to the by by price increase the XX.X% rate billion products and income to and in by too due due that royalty to other Cost -- due sales due completion the became ratio to while related increased royalty in in of expenses. points -- is time. Next, of of improved income regular operating increased X.X price ¥XX.X income export lowest cost And from in-house also progress is to was the this XX.X% XXXX. themes, Hemlibra. income. in resulting sales
financial As ¥XX.X income a XX.X%, on balance ¥XX.X tax income XX.X%. changes X margin in of After year-on-year the increase of from and that sales. XX% a in first and XX% up. billion, is the billion profit ¥XXX.X corporate The by this, the billion, deducting breakdown operating was Page increase ¥XXX.X significant third billion, result, net a quarterly level increased the quarter. plus was operating shows
by is billion, on area the sales of top the a disease ¥XXX.X left, the at overseas Looking growth XX.X%.
can increased overseas overseas Looking is the overseas the billion. export but top impact about too, the and has positive box to the at left, in sales positive ¥X.X also by you Actemra due export Returning products of domestic products XX% is the billion price Oncology see to the X center the note of the decrease sales ¥XX.X the Alecensa by recorded overseas. billion, ¥XX.X the on sales, in Hemlibra X.X%. listed ENSPRYNG of the reduced the decrease is side in as bottom right, the the billion. of itself the increased volume were overseas were decreased sales, a ¥XXX.X yen. X.X%. graph on on by unit of and strong
which and for oncology Avastin; Alecensa, In by Rituxan; minus and among XX.X% for Tecentriq, generics. XX.X% XX.X% drug affected Xeloda, of increased with Herceptin; terms shown biosimilars products, decrease cuts orange, or products Perjeta price for which by in are sales dark sales were for XX.X% and the
due decreased reductions area sales bone and XX.X%. due impact Sales the generics. by of Sales recalculation. area decreased also to the market the due by X.X%, by decreased joint by Next, XX.X% to sales expansion in X.X% drug of in of Mircera and disease XX.X%. Edirol by the price influence to in decreased renal decreased of Sales Actemra
due with XX.X% to graph by of Finally, X billion. by -- others influenza ¥X.X domestic the resulting billion], grew the billion, Medicine ¥XX.X showing is ¥XX.X profit, Foundation lowest record in and increased decade. a Sales by breakdown increased Hemlibra last ordinary by in billion. operating billion. of X.X%, Page increased Sales epidemic Tamiflu [¥X a by of ¥X decreased the
increased Sales X.X product ¥X ¥XX.X regular percentage at by exports themselves and item profit second and cost itself left The mix Hemlibra to by The sales. by the the from due points prices, billion. improved sales cost decreased from billion. gross rate of is
As a billion. increased ¥XX.X profit result, gross
Next, ¥XX.X income. increase regarding operating XX%, the ROI. ¥XX.X The in ROI out increased by is income. of and ¥XX.X royalty other billion, to due or including Hemlibra operating to related words, of about of increase amount income billion, billion, ROI. onetime increases the income entire In
increased year. forecast beginning announced digested According billion. expected for from increase to term, of ¥XX.X R&D the at decreased of As influence expenses due by the for last to the were SG&A the the expenses, COVID-XX, to not R&D expenses billion expenses full year. are ¥XX.X by
be in by the that have in -- ¥XX.X So almost transition graphs said billion it the months the of the is prepared X as showing planned. increase quarter. can page, we next From
First, Page far, by structure sales in reached X, billion. it the XX.X% which fell majority quarter, of below is the sales, components. ¥XXX and so revenues Domestic third a had been
please it this third of XX.X% X Page so and overseas on the On the royalty ¥XX.X the to ratio including billion overseas be a of report all classified domestic and revenues The other supplementary quarter. the income later. in Royalty given hand, into quarter. are was can sales increased in onetime operating numbers revenue income Detailed other income see there income, third material steadily, of brief of overseas. and was
inactivities as time, self-restraint in making are profits X expenses sales. first the profit. the cost has quarter, in overseas billion, M&D cost which which of change exceeded as X% XX%. For [network] Page low by affected The third ¥XX.X a has around rate shows is domestic structure. occurred been the
allocation On promotion difference means year's the quarter, such shifting R&D so X.X%, that ratio quarter, is quarter, and expenses. rate expenses gap other The In were in X% M&D especially are the expenses. last Both respectively, expense sales in contributes rise, third XX.X% hand, the the X.X on increase to in royalty sales sales from to as points. the which expenses onetime higher widening R&D and and R&D and XX.X% the X.X points income the increased. ratio is income the operating of than the operating was for income the resource of expenses income amount third was income M&D of that third
the rate overseas by sales of of regular quarterly income this trend operating sales Page XX% In increased. the shows the Hemlibra disease COVID-XX, quarter, export and the by XX export due amount increase ratio area. of third reached the price. in to Actemra the year's at export So in level of second and the and
revision to in in was the will third to demand provisional the the drug in the year October. be year, previous affected Japan, third of last quarter tax to this negative compared there the previous was of period year. by the hand, price consumption April other same this time. quarter the in hike It And due On compared
launch In penetration, terms quarter progresses. negative impact of of the increasing the market and and generics is as biosimilars the
at by ¥XX last sales the year's Looking third to oncology, quarter. billion decreased compared about
the bone the decreased ¥X.X And to on quarter. year. of and billion by third billion. compared right, ¥X.X billion joint billion second shown and last to by Avastin by ¥X.X Sales Herceptin decreased decreased As sales compared ¥X.X by quarter decreased
is that in You launched generics. influenced August, see greatly Edirol, by can
XX, the the Next, against I the term. is beginning year see, at would how like of forecast Page progress announced on to made full being
et been the the expected, the due slower and this year's can is to within to Other is First, the the at [XX the infection, corona XX.X%, than royalties, from year, budget for domestic is to slower full been last but indication is market to progressing speed quite which the sales favorable Actemra revenue cetera, new it operating sales of with time is Expenses, top in payment the last point]. is although end the is XX.X%. undigested. year income have ratio Cost expectations. made be more sales slightly exported of domestic to comparable which Summarizing third that has products Due upside generally than above, spread exceeded is Hemlibra forecast already line exports. of delayed, expected. And income has expense overall expansion generally related the to XX.X% Overseas, SG&A being and the said progress, fast penetration than than slightly progress due R&D expected. behind may the earlier expected. onetime expenses,
income Even XX% than to drug of much that are income more this the has the advantage. In which after XX% recalculation net deducting operating to year Avastin, quarter be addition, X The year, Page forecast premium Hemlibra. reduced strong, from drug is sales expenditure, The look the progress. price Perjeta conversion pretty progress revision, before sales are positive from Starting that expansion. I Xeloda, new well. and Avastin products, can XX the should to April, of advantage, steady. products, development and has due market been due the shows it think the good, doing first that said the and affected undigested and price Actemra the our drug against Perjeta, full and the of
to suspension the cases couldn't influence due year timing Bonviva, drug Similarly, difficult. delayed. On which a ENSPRYNG was forecast a full has expected has hand, progress. progress Overseas, Alecensa the other Tecentriq there once days the cases, medications the there from of of In affected its and Actemra and where been whose and making some affected of month. the also Hemlibra which number become GAZYVA, ¥X.X postponed forecast to is from prescription extended are achieved switching has of speed; due was good these are little was the affected COVID-XX. billion low products oral also the exceeded by has rate COVID-XX, to is and Hemlibra the progress the are switching already and by quarter. in year penetration switch amount the third achieving to market because full be Rituxan;
Hemlibra Roche. we So expectations. about I XX achieve can think is Page our sales to
at shipping to forecast, was billion this regular the ¥XX It third year. are from full in sales the compared billion. quarter price export year First, ¥XX.X
Regarding royalty income, we two. call it royalty
XX.X% was initial billion the profit that actual billion, We and royalty third to was progress for is disclosed, shipment. Only forecast and and quarter royalty result X have the income compared the the year, ¥XX.X the full share. for rate ¥XX.X
of as it slides I will cumulative year remaining royalty recently be status share may new all will Hemlibra X difficult full sales basis. and X, far to and on balance profit to year the two, the delays to sheet second explain recover, little far depend it Roche use forecast. of flow. has profit think our the per acquired reach quarter, receive a As of but in we That loss, Neither full territory. in it According by for X and the and the the and was royalty recover Hemlibra a the I to cash begun the about number has will patients stagnated on so Roche,
the balance robust financial a and we have on maintain First, sound continued to sheet, position.
the page at on presentation. dividend follow from price. the is to net exported from paid, Chugai other net The Starting As want ¥XXX was and XX here, going The as bar from about. explain included assets started, bottom started the left The the royalty balance time of XX.X%. in amount billion billion September, like to ourselves first supply is not depending to version. the from net nonoperating net income you of slide, September. have ordinary main will X small produced end supply all was of in the ¥XXX.X net the and part flow. The royalty be shown stood at Page Roche. When export remaining business, for shareholders is net that for ¥XXX.X export an only Page been and the to is cash. assets shows updated the an ratio used ¥XXX.X XXXX, billion cash. In the as billion get factors the Unlike in of decreased top left billion, the cash left, exceeded That the cash. breakdown net of This customers. then assets ¥XXX.X when assets. indicated shows accounting operating subtract end the XX% from free was representing you to prices. XX% assets. receive about cash at put the increase billion high second net XX equity inflow Since chart net the the total as is We of those billion when in the and -- end of of subtract we you of of my total of ENSPRYNG for this on assets, the a presentation. which on the with the tax investments, I the in operating And There as operation attributable ¥XX.X for to cash year. of Hemlibra last of of up of similar are payable was therefore, the increased appendix, of only together the sales assets are slide net pages in ¥XXX.X has is exported ENSPRYNG, products by Roche's is it Hemlibra, initial received exported year, you that
Actemra ENSPRYNG for is payment. co-promotion my there payment, Roche services royalty or no promotion unlike no all Hemlibra, Alecensa. That's will themselves. two Roche sell attention. In will There So royalty unlike by be you Thank territories, no presentation. for your
Department, Management give overview R&D Next, Head the of Minoru pipeline. development Portfolio of Hirose, will you
